Table 3.
Age (years, range) | |
Mean | 59.06 (33–80) |
Gender (n, %) | |
Male | 19 (54.29%) |
Female | 14 (40.00%) |
NA | 2 (5.71%) |
Diagnosis of cancers (n, %) | |
Metastatic renal cell cancer | 10 (28.57%) |
Metastatic colorectal cancer | 6 (17.14%) |
Metastatic breast cancer | 5 (14.29%) |
Other cancers | 14 (40.00%) |
Metastatic non-small-cell lung cancer | 4 |
Glioblastoma multiforme | 2 |
Medullary thyroid cancer | 2 |
Malignant parotid tumour | 1 |
Pancreatic cancer | 1 |
Metastatic hepatocellular carcinoma | 1 |
Metastatic carcinoid cancer | 1 |
Metastatic oesophageal cancer | 1 |
Presenting complaints (n, %) | |
Jaw pain | 12 (34.29%) |
Jaw pain with other complaints | 6 (17.14%) |
Asymptomatic | 8 (22.86%) |
Jaw discomfort | 1 (2.86%) |
Spontaneous teeth loss | 1 (2.86%) |
Limited mouth opening and submandibular area swelling | 1 (2.86%) |
Gingival bleeding | 1 (2.86%) |
NA | 5 (14.29%) |
Clinical presentation (n, %) | |
Bone exposure MRONJ | 32 (91.43%) |
Nonexposed MRONJ | 3 (8.57%) |
Location | |
Mandible | 29 (82.86%) |
Maxilla | 4 (11.43%) |
NA | 2 (6.67%) |
Types of antiangiogenic agents (n, %) | |
Bevacizumab | 14 (40%) |
Aflibercept | 5 (14.29%) |
Sunitinib | 3 (8.57%) |
Cabozantinib | 2 (5.71%) |
Sorafenib | 1 (2.86%) |
Temsirolimus | 1 (2.86%) |
Everolimus | 1 (2.86%) |
Dasatinib | 1 (2.86%) |
Multiple antiangiogenic agents | 7 (20.00%) |
Route of antiangiogenic administrations (n, %) | |
Intravenous administration | 21 (60.00%) |
Oral administration | 12 (34.29%) |
Combination of intravenous administration and oral administration | 2 (5.71%) |
Time to MRONJ (months, 95% CI) | |
Intravenous antiangiogenics | 6.49 (2.67–10.30) |
Oral antiangiogenics | 16.72 (2.59–30.84) |
Predisposing factors (n, %) | |
Extraction | 13 (37.14%) |
Periodontal disease | 3 (8.57%) |
Minor trauma from use of denture | 4 (11.43%) |
Dental implant | 1 (2.86%) |
Mean time to MRONJ after extraction (months, 95% CI) | 3.09 (0.40–5.77) |
Management of MRONJ (n, %) | |
Surgical treatment | 17 (48.57%) |
Minimally invasive surgical procedures | 11 |
Major surgical procedures | 6 |
Nonsurgical treatment | 16 (45.71%) |
No treatment | 1 (2.86%) |
NA | 1 (2.86%) |
Treatment outcomes (n, %) | |
Disease resolution | 18 (62.06%) |
Mean time to resolution (months, 95% CI) | 6.75 (0.90–12.59) |
Incomplete resolution | 11 (37.93%) |
NA | 6 |
NA: not available.